← FDA DRUG APPROVALS

FDA ANDA · ANDA203730

DIVALPROEX SODIUM

Sponsor: AMNEAL PHARMS

APPLICATION
ANDA203730
TYPE
ANDA
ORIGINAL APPROVAL
2015-05-29
LATEST ACTION
2020-01-08
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

DIVALPROEX SODIUMPrescription
DIVALPROEX SODIUM EQ 500MG VALPROIC ACID · TABLET, EXTENDED RELEASE · ORAL
DIVALPROEX SODIUMPrescription
DIVALPROEX SODIUM EQ 250MG VALPROIC ACID · TABLET, EXTENDED RELEASE · ORAL

Approval history

2020-01-08Labeling · Supplement 8 · standardAP
2020-01-08Labeling · Supplement 4 · standardAP
2020-01-08Labeling · Supplement 7 · standardAP
2020-01-08Labeling · Supplement 10 · standardAP
2015-05-29UNKNOWN · OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →